Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...